

Information Regarding Clinical Trial

Title	Phase 1B, multicenter, open label study of PDR001 in combination with platinum-doublet chemotherapy in PD-L1 unselected, metastatic NSCLC patients.
Protocol Number	CPDR001C2101
Sponsor	Novartis
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	Dose Expansion Phase- Group B treatment naïve treated CNS mets eligible Known EGFR/ALK negative prior neoadj/adj tx counts if PD >12m